Last €48.08 EUR
Change Today -0.455 / -0.94%
Volume 77.7K
GXI On Other Exchanges
Symbol
Exchange
Xetra
OTC US
OTC US
As of 1:55 PM 04/24/14 All times are local (Market data is delayed by at least 15 minutes).

gerresheimer ag (GXI) Snapshot

Open
€48.77
Previous Close
€48.53
Day High
€48.94
Day Low
€47.78
52 Week High
01/22/14 - €54.22
52 Week Low
06/24/13 - €41.64
Market Cap
1.5B
Average Volume 10 Days
169.1K
EPS TTM
€1.98
Shares Outstanding
31.4M
EX-Date
05/2/14
P/E TM
24.3x
Dividend
€0.70
Dividend Yield
1.35%
Current Stock Chart for GERRESHEIMER AG (GXI)

Related News

No related news articles were found.

gerresheimer ag (GXI) Related Businessweek News

No Related Businessweek News Found

gerresheimer ag (GXI) Details

Gerresheimer AG manufactures and sells specialty glass and plastic products primarily for the pharma and healthcare industry worldwide. It operates in four divisions: Plastic Systems, Moulded Glass, Tubular Glass, and Life Science Research. The Plastic Systems division offers customer-specific plastic systems for pharmaceuticals, diagnostics, and medical technology, such as asthma inhalers, insulin pens, and lancets; and plastic containers as primary packaging for pharmaceuticals and healthcare. This division also offers drug delivery systems; medical technology products; and containers for solid and liquid dosage, ophthalmic and rhinological applications, and parenteral packaging. The Moulded Glass division produces bottles and jars for pharmaceuticals, including syrup and dropper bottles, tablet jars, wide-neck jars, injection bottles, and infusion and transfusion bottles; flacons and pots for cosmetics; and bottles and jars for beverages and food. The Tubular Glass division produces and sells glass products, including glass tubes, ampoules, vials, cartridges, and prefillable syringe systems. The Life Science Research division offers reusable laboratory glassware, such as beakers, erlenmeyer flasks, precision burettes, pharmaceutical graduates, and cylinders; disposable laboratory glassware comprising serological pipettes, culture tubes, and chromatography and scintillation vials; and special laboratory glassware consisting of NMR tubes, chromatography columns, and products for tissue preparation. Gerresheimer AG was founded in 1864 and is headquartered in Dusseldorf, Germany.

11,191 Employees
Last Reported Date: 04/10/14
Founded in 1864

gerresheimer ag (GXI) Top Compensated Officers

Chairman of the Management Board and Chief Ex...
Total Annual Compensation: €1.1M
Chief Financial Officer and Member of Managem...
Total Annual Compensation: €855.0K
Member of the Management Board
Total Annual Compensation: €735.0K
Compensation as of Fiscal Year 2013.

gerresheimer ag (GXI) Key Developments

Gerresheimer AG Schedule to Start Construction of its Own Greenfield Indian Vial Plant in Kosamba

Gerresheimer AG announced that in Primary Pharmaceutical Packaging Glass, the company has scheduled to start construction of its own greenfield Indian vial plant in Kosamba.

Gerresheimer AG Reports Earnings Results for the First Quarter of 2014; Provides Earnings Guidance for the Year 2014

Gerresheimer AG reported earnings results for the first quarter of 2014. The company generated revenues of EUR 297.5 million in the first quarter of financial year 2014 (December 1, 2013 to November 30, 2014), marking 0.3% revenue growth on the prior-year quarter. At constant exchange rates, revenues came to EUR 304.2 million, representing growth of 3.2%. Revenues went up substantially on customer-specific drug-delivery devices such as insulin pens, inhalers, prefillable syringe systems and pharmaceutical plastic packaging. The company generated adjusted EBITDA of EUR 47.6 million in the first quarter of 2014, an increase of 3.3% on the prior-year figure. Adjusted earnings per share, at EUR 0.38, exceeded the EUR 0.36 recorded in the prior-year quarter. As planned, the company incurred capital expenditure of EUR 21.7 million in the first quarter. Capital expenditure focused on adding production capacity for medical plastic systems such as insulin pens and inhalers in Horsovsky Tyn, Czech Republic, and Peachtree City, USA. Net income went up by 0.8% to EUR 10.3 million. As before, the company anticipates revenue growth of 4% to 6% at constant exchange rates for financial year 2014. The company continues to expect adjusted EBITDA to be in a range of between EUR 250 million and EUR 265 million at constant exchange rates. Capital expenditure in financial year 2014 will be on a par with the preceding financial year, representing some 9% to 10% of exchange rate adjusted revenues.

Gerresheimer AG, Q1 2014 Earnings Call, Apr 10, 2014

Gerresheimer AG, Q1 2014 Earnings Call, Apr 10, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GXI:GR €48.08 EUR -0.455

GXI Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Becton Dickinson and Co $114.15 USD +0.45
Jabil Circuit Inc $18.00 USD +0.205
Piramal Glass Ltd 110.15 INR +0.35
View Industry Companies
 

Industry Analysis

GXI

Industry Average

Valuation GXI Industry Range
Price/Earnings 24.4x
Price/Sales 1.2x
Price/Book 3.0x
Price/Cash Flow 24.4x
TEV/Sales 0.7x
 | 

Post a JobJobs

View all jobs

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GERRESHEIMER AG, please visit www.gerresheimer.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.